Abstract
Temozolomide (TMZ) is widely used to treat glioblastoma multiforme (GBM). Although the MGMT gene methylation status is postulated to correlate with TMZ response, some patients with a methylated MGMT gene still do not benefit from TMZ therapy. Cancer stem cells (CSCs) may be one of the causes of therapeutic resistance, but the molecular mechanism underlying this resistance is unclear. microRNA (miRNA) deregulation has been recognized as another chemoresistance modulating mechanism. Thus, we aimed to evaluate the miRNA expression patterns associated with chemoresistance that is dependent on the CSC status in GBM tumors to identify therapeutic biomarkers. CSCs were identified in 5 of 20 patients’ tumor tissues using magnetic separation. CSC (+) tumors displayed a significant induction of CpG island methylation in the MGMT gene promoter (p = 0.009). Using real-time reverse transcription polymerase chain reaction (qRT-PCR), 9 miRNAs related to GBM (mir-181b, miR-153, miR-137, miR-145, miR-10a, miR-10b, let-7d, miR-9, and miR-455-3p), which are associated with cell cycle and invasion was analyzed in tumor samples. Low miR-181b and high miR-455-3p expression levels were detected (p = 0.053, p = 0.004; respectively) in CSC (+) tumors. Analysis revealed a significant correlation between miR-455-3p expression and Smad2 protein levels as analyzed by immunohistochemistry in CSC (+) tumors (p = 0.002). Thus, miR-455-3p may be involved in TMZ resistance in MGMT methylated CSC (+) GBM patients. Further studies and evaluations are required, but this miRNA may provide novel therapeutic molecular targets for GBM treatment and new directions for the development of anticancer drugs.
Similar content being viewed by others
References
Altaner C (2008) Glioblastoma and stem cells. Neoplasma 55:369–374
Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
Bier A, Giladi N, Kronfeld N et al (2013) MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4(5):665–676
Bisso A, Faleschini M, Zampa F et al (2013) Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 12(11):1679–1687
Brescia P, Ortensi B, Fornasari L et al (2013) CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 31(5):857–869
Bruna A, Darken RS, Rojo F et al (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11(2):147–160
Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866
Calin GA, Pekarsky Y, Croce CM (2007) The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20(3):425–437
Cecener G, Tunca B, Egeli U et al (2012) The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol 32(2):237–244
Cheng WY, Kandel JJ, Yamashiro DJ et al (2012) A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PLoS One 7(4):e34705
Dirks PB (2005) Brain tumor stem cells. Biol Blood Marrow Transpl 11(2 Suppl 2):12–13
Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259–269
Everhard S, Tost J, El Abdalaoui H et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11(4):348–356
Galli R, Binda E, Orfanelli U (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021
Guessous F, Alvarado-Velez M, Marcinkiewicz L et al (2013) Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 112(2):153–163
Haapa-Paananen S, Chen P, Hellström K et al (2013) Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. PLoS One 8(4):e60930
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003
Hemmati HD, Nakano I, Lazareff JA et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178–15183
Hirata H, Hinoda Y, Ueno K et al (2012) MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33(1):41–48
Hummel R, Hussey DJ, Haier J (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46(2):298–311
Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347
Ignatova TN, Kukekov VG, Laywell ED et al (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193–206
Jeon HM, Sohn YW, Oh SY et al (2011) ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 71(9):3410–3421
Jones DT, Kocialkowski S, Liu LETAL (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673–8677
Kloth JN, Kenter GG, Spijker HS et al (2008) Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol 21(7):866–875
Koo S, Martin GS, Schulz KJ et al (2012) Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. BMC Cancer 10(12):143
Kreth S, Limbeck E, Hinske LC et al (2013) In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol 125(5):671–681
Lathia JD, Gallagher J, Myers JT et al (2011) Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One 6(9):e24807
Lee ST, Chu K, Oh HJ et al (2011) Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 102:19–24
Lee HK, Bier A, Cazacu S et al (2013) MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One 8(2):e54652
Leibetseder A, Ackerl M, Flechl B et al (2013) Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro Oncol 15(1):112–121
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicated that thousands of human genes are microRNA targets. Cell 120:15–20
Li Y, VandenBoom TG 2nd, Kong D et al (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69(16):6704–6712
Li P, Lu X, Wang Y et al (2010) MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res 24(6):436–443
Liu G, Yuan X, Zeng Z et al (2006) Analysis of gene expression and chemoresistance of CD133+cancer stem cells in glioblastoma. Mol Cancer 5:67
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Δ Δ C(T)) method. Methods 25:402–408
Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
M-Chang CJ, Hsu CC, Chang CH et al (2011) Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep 26(4):1003–1010
Melguizo C, Prados J, González B et al (2012) MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med 17(10):250
Munoz JL, Bliss SA, Greco SJ et al (2013) Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids 1(2):e126
Nakano I, Kornblum HI (2006) Brain tumor stem cells. Pediatr Res 59(4 Pt 2):54R–58R
Nishida N, Yamashita S, Mimori K et al (2012) MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 19(9):3065–3071
Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007
Okamoto OK, Oba-Shinjo SM, Lopes L et al (2007) Expression of HOXC9 and E2F2 are up-regulated in CD 133+ cells isolated from human astrocytomas and associated with transformation of human astrocytes. Biochim Biophys Acta 1769:437–442
Oliver TG, Wechsler-Reya RJ (2004) Getting at the root and stem of brain tumors. Neuron 42:885–888
Persano L, Pistollato F, Rampazzo E et al (2012) BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis 18(3):e412
Pistollato F, Abbadi S, Rampazzo E et al (2010) Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28:851–862
Ramakrishnan V, Kushwaha D, Koay DC et al (2011) Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas. Cancer Biomark 10(3–4):185–193
Rani SB, Rathod SS, Karthik S et al (2013) MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol 15(10):1302–1316
Revelos K, Petraki C, Gregorakis A et al (2005) Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25(4):3123–3133
Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111
Rorke LB (1997) Pathologic diagnosis as the gold standard. Cancer 79:665–667
Sanchez-Martin M (2008) Brain tumour stem cells: implications for cancer therapy and regenerative medicine. Curr Stem Cell Res Ther 3:197–207
Sato A, Sunayama J, Matsuda K et al (2011) MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 29(12):1942–1951
Shi L, Cheng Z, Zhang J et al (2008) hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236:185–193
Shi M, Du L, Liu D et al (2012) Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 228(2):148–157
Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
Swingler TE, Wheeler G, Carmont V et al (2012) The expression and function of microRNAs in chondrogenesis and osteoarthritis. Arthritis Rheum 64(6):1909–1919
Sze CI, Su WP, Chiang MF et al (2013) Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas. Front Oncol 19(3):59
Takwi AA, Wang YM, Wu J et al (2013) miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene. doi:10.1038/onc.2013.330
Tunca B, Tezcan G, Cecener G et al (2012) Olea europaea leaf extract alters microRNA expression in human glioblastoma cells. J Cancer Res Clin Oncol 138(11):1831–1844
Ujifuku K, Mitsutake N, Takakura S et al (2010) miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296(2):241–248
Valledor AF, Arpa L, Sanchez-Tillo E et al (2008) IFN-{gamma}-mediated inhibition of MAPK phosphatase expression results in prolonged MAPK activity in response to M-CSF and inhibition of proliferation. Blood 112(8):3274–3282
Visone R, Veronese A, Rassenti LZ et al (2011) miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118(11):3072–3079
Wang B, Hsu SH, Majumder S et al (2010) TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29(12):1787–1797
Wang B, Li W, Guo K et al (2012) miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 421(1):4–8
Wang J, Sai K, Chen FR et al (2013) miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 72(1):147–158
Weller M, Pfister SM, Wick W et al (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370–e379
Wu W, Pew T, Zou M et al (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280(6):4117–4124
Zhang L, Sato E, Amagasaki K et al (2006) Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor. J Neurosurg 105:119–128
Zhang L, Pickard K, Jenei V et al (2013) miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res 73(21):6435–6447
Zhao S, Deng Y, Liu Y et al (2013) MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol Biol Rep 40(4):2789–2798
Zhu W, Shan X, Wang T et al (2010) miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127(11):2520–2529
Zhu DX, Zhu W, Fang C et al (2012) miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33(7):1294–1301
Zhu X, Li Y, Shen H et al (2013) miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 45(2):80–86
Acknowledgments
This study was supported by a grant from the Scientific Research Projects Foundation (BAP) of the Uludag University of Turkey [Project No. OUAP (T)-2012/17].
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tezcan, G., Tunca, B., Bekar, A. et al. microRNA Expression Pattern Modulates Temozolomide Response in GBM Tumors with Cancer Stem Cells. Cell Mol Neurobiol 34, 679–692 (2014). https://doi.org/10.1007/s10571-014-0050-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-014-0050-0